コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
2 ater than 100 microM included 3',5'-diiodo-L-thyronine (3',5'-l-T2), 3-iodo-L-thyronine (L-T1), 3'-io
4 othyronine (reverse T3; r-T3), 3,3'-diiodo-L-thyronine (3,3'-l-T2) and 3,5-diiodo-L-thyronine (3,5-D-
5 diiodo-l-thyronine (3,5-T(2)), 3,3'-diiodo-l-thyronine (3,3'-T(2)), and 3-iodo-l-thyronine (3-T(1)),
7 5'-triiodo-l-thyronine (rT(3)), 3,5-diiodo-l-thyronine (3,5-T(2)), 3,3'-diiodo-l-thyronine (3,3'-T(2)
8 diiodo-l-thyronine (3,3'-T(2)), and 3-iodo-l-thyronine (3-T(1)), in the brain and thyroid gland (TG)
9 tatively identified metabolite (3-monoiodo-l-thyronine 4-O-sulfate), and an unidentified feature (590
10 s of two thyroxine analogs, 3,3',5-triiodo-L-thyronine and 3,3',5-triiodothyroacetic acid, on purifie
12 ycholate, 5-leuenkephalin, triiodothyronine, thyronine, dabsyl-L-valine, and N-benzoyl-L-arginyl-4-am
13 iral forms of thyroxine, diiodotirosine, and thyronine in human milk, with potential implications for
15 5'-diiodo-L-thyronine (3',5'-l-T2), 3-iodo-L-thyronine (L-T1), 3'-iodo-L-thyronine (3'-L-T1), and L-t
16 arkedly decreased serum T3 (3,3 ,5-triiodo-l-thyronine), maternal hepatotoxicity, and increased multi
18 riiodo-l-thyronine (T(3)), 3,3',5'-triiodo-l-thyronine (rT(3)), 3,5-diiodo-l-thyronine (3,5-T(2)), 3,
19 yl derivatives sharing the GC-1 halogen-free thyronine scaffold.(4) One compound (NH-3) is a T(3) ant
20 -iodo-L-thyronine and 3,5,3',5'-tetra-iodo-L-thyronine secretion did not alter isoform switching, sug
21 shown that the late-term rise in tri-iodo-l-thyronine (T(3) ) in fetal sheep leads to the inhibition
22 the effects of MB07811 with 3,5,3'-triiodo-l-thyronine (T(3)) and a non-liver-targeted TR agonist, 3,
24 ix THs, l-thyroxine (T(4)), 3,3',5-triiodo-l-thyronine (T(3)), 3,3',5'-triiodo-l-thyronine (rT(3)), 3
25 were performed in control, 10-day triiodo-l-thyronine (T(3))-treated (model of increased UCP3 expres
30 Thyroid hormones such as 3,3',5 triiodo-L-thyronine (T3) control numerous aspects of mammalian dev
35 xisome proliferators (PPs), 3,3',5-triiodo-L-thyronine (T3), and 9-cis retinoic acid (9-cis RA) induc
36 d the role of the hormone, 3,3', 5-triiodo-L-thyronine (T3), in the nuclear translocation and targeti
37 orted that thyroid hormone, 3,3',5-triiodo-l-thyronine (T3), increased Na,K-ATPase activity of adult
38 nteractions with the ligand 3,3',5 triiodo-l-thyronine (T3), RXR, DNA, and co-activators such as SRC1
39 omparing the repertoires of 3,3',5-triiodo-L-thyronine (T3)-responsive genes of two neural cell lines
41 hormones (L-thyroxine, T4; 3,5,3'-triiodo-L-thyronine, T3) and is overexpressed in ovarian cancer.
42 igated how thyroid hormone (3,5',5-triiodo-l-thyronine, T3) inhibits binding of thyroid hormone recep
43 esponse to thyroid hormone (3,5,3'-triiodo-l-thyronine, T3) is a dynamic and cell-type specific proce
45 0.24 mM, whereas thyroid hormone (triiodo-L-thyronine, T3) stabilizes an inactive monomeric form of
47 -thyroxine (TT(4)), total 3,3',5-triiodo-(L)-thyronine (TT(3)), and total 3,3',5'-triiodo-(L)-thyroni
49 ind triiodothyronine (T(3), 3,5,3'-triiodo-l-thyronine) with high affinity, and its precursor thyroxi